Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linsitinib - Sling Therapeutics

Next Previous
Drug Profile

Linsitinib - Sling Therapeutics

Alternative Names: ASP-7487; Linsitinib - Astellas Pharma; OSI-906; OSI-906AA

Latest Information Update: 21 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer Astellas Pharma; Multiple Myeloma Research Foundation; Sling Therapeutics
  • Class Cyclobutanes; Imidazoles; Pyrazines; Quinolines; Small molecules
  • Mechanism of Action IGF type 1 receptor antagonists; Insulin receptor antagonists; Protein tyrosine kinase inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenocortical carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Graves ophthalmopathy
  • No development reported Autoimmune disorders; Unspecified
  • Discontinued Adrenocortical carcinoma; Liver cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 04 Aug 2026 Phase-III clinical trials in Graves ophthalmopathy in USA (PO) (NCT07753603)
  • 28 Jul 2026 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
  • 28 Jul 2026 No recent reports of development identified for preclinical development in Unspecified in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top